The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients
J. Wu1, S. Yin1, F. Zhang1, L. Wu1, X. Wang2, T. Lin1
1urology, west china hospital, Chengdu, China, 2Urology, West China Hospital, Chengdu, China
Meeting: 2022 American Transplant Congress
Abstract number: 9087
Keywords: Hepatitis B, Kidney/liver transplantation, Viral therapy
Topic: Clinical Science » Infection Disease » 27 - Non-Organ Specific: Viral Hepatitis
Session Information
Session Name: Non-Organ Specific: Viral Hepatitis
Session Type: Poster Abstract
Date: Tuesday, June 7, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: To explore the prevalence and risk factors of de novo HBV infection (DNH) in kidney transplantation (KT) from HBsAg⁺ donors (D[HBsAg⁺]) to HBsAg-negative recipients (R[HBsAg‾]).
*Methods: D(HBsAg⁺)/R(HBsAg‾) KTs were included consecutively between July 2017, and December 2020. Systematic search and pooled analysis were conducted to estimate the prevalence of DNH.
*Results: 81 donors were HBV DNA⁺, 12 were HBeAg⁺, and 63 received antiviral treatment before donation. 26 recipients were anti-HBs antibody (HBsAb)-negative. Lower DNH rate was observed if the donors received antiviral treatment compared to those not (4/42[9.5%] vs 0/63[0.0%], P=0.023). In 8 HBeAg⁺ donors receiving antiviral treatment, no recipient developed DNH while 1 developed in 4 HBeAg⁺ donors not. Among donors with initial HBV DNA >100IU/mL, higher DNH rate was observed if donors did not receive antiviral treatment (3/26[11.5%] vs 0/44[0%], P=0.059). Higher DNH rate was also observed in HBsAb‾ recipients compared with HBsAb⁺ recipients (0/79[0%] vs 4/26[15.3%], P=0.002). Pooled analysis included another 11 studies, showing the prevalence of DNH were 3/106[2.83%] and 1/321[0.31%] in HBsAb⁺ recipients, and 5/27[18.52%] and 1/20 [5.00%] in HBsAb‾ recipients receiving HBV DNA⁺ and HBVDNA‾/HBsAg⁺ kidneys, respectively.
*Conclusions: In D(HBsAg⁺)/R(HBsAg‾) KTs, donors’ positive HBeAg or viral loads> 100 IU/mL increased the risk of DNH, but donors’ antiviral treatment can decrease the risk. In donors with viral loads<100IU/mL, kidneys can be safely transplanted into HBsAb⁺ recipients without donors’ antiviral treatment.
To cite this abstract in AMA style:
Wu J, Yin S, Zhang F, Wu L, Wang X, Lin T. The Prevalence And Risk Factors Of De Novo Hepatitis B Virus Infection In Kidney Transplantation From Hepatitis B Antigen-positive Donors To Hbsag-negative Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/the-prevalence-and-risk-factors-of-de-novo-hepatitis-b-virus-infection-in-kidney-transplantation-from-hepatitis-b-antigen-positive-donors-to-hbsag-negative-recipients/. Accessed December 11, 2024.« Back to 2022 American Transplant Congress